Therefore, targeting the PTMs and kinase activity of SRPK1 has the potential to re-sensitize breast cancer cells to chemotherapy, and this strategy has the advantage of being titratable and reversible as compared with other approaches, such as genetic manipulation. This evidence concerns the gene SRPK1 and breast carcinoma.